Urinalysis Market Size, Share & Forecast 2026-2033

Overview

The Global Urinalysis Market size was valued at USD 5.1 billion in 2025 and is expected to reach USD 9.8 billion by 2033, growing with a CAGR of 8.6% during the forecast period 2026-2033. The rising prevalence of bladder cancer is driving growth in the global urinalysis market by increasing the demand for non-invasive, early detection, and monitoring solutions based on urine analysis.

Urinalysis plays an important role in bladder cancer screening and management by detecting abnormalities such as blood in urine (hematuria), cancer-related biomarkers, and other indicators that support diagnosis and disease monitoring. According to the study “The Global Landscape of Bladder Cancer Incidence and Mortality in 2020 and Projections to 2040,” bladder cancer accounted for approximately 573,000 new cases and 213,000 deaths worldwide in 2020, with annual cases and deaths projected to increase by 72.8% and 86.6%, respectively, by 2040.

Modern urinalysis analyzers has evolved beyond routine urine analysis to support comprehensive kidney function testing, pregnancy and fertility testing, urine protein testing, and the detection of urine biomarkers associated with chronic kidney disease, urinary tract infections, bladder cancer, and metabolic disorders. The growing use of urine dipsticks, urine reagent strips, and urine test kits across hospitals, diagnostic laboratories, and home-care settings is improving access to rapid, non-invasive screening while supporting earlier clinical decision-making.

This rising disease burden is also driving demand for advanced urine-based diagnostic technologies that enable earlier detection and improved patient management. In December 2025, Yenos Analytical launched the Yenos Test, a direct-to-consumer urine-based multi-cancer detection test that uses microRNA biomarkers and nanopore-array technology to detect six cancers with 97% sensitivity and specificity, expanding the role of urine-based diagnostics beyond conventional testing. Such innovations, combined with the growing need for accessible and minimally invasive cancer screening methods are expected to broaden the clinical adoption of urine-based diagnostics worldwide.

Drivers

Rising Global Burden of Chronic Kidney Disease (CKD)

The rising global burden of chronic kidney disease (CKD) is driving growth in the urinalysis market by increasing the demand for early detection, routine monitoring, and disease management tools that assess kidney function and urinary abnormalities. Urinalysis is a critical diagnostic approach for CKD screening as it supports kidney function testing by identifying urine biomarkers such as proteinuria, albuminuria, and other indicators of renal impairment, enabling timely intervention and continuous monitoring of disease progression.

According to a global trends and projection study based on Global Burden of Disease (GBD) data, newly diagnosed CKD cases increased from approximately 7.8 million in 1990 to nearly 20 million in 2021 and are projected to reach around 25.1 million by 2030, with CKD incidence rates continuing to rise worldwide. The growing prevalence of CKD among older adults, individuals with diabetes and hypertension, and populations in middle- and high-middle socio-demographic regions is creating strong demand for advanced urinalysis solutions in hospitals, diagnostic laboratories, and point-of-care settings.

As healthcare systems emphasize early diagnosis, preventive care, and effective management of kidney disorders, demand for automated urine analyzers, urine reagent strips, urine dipsticks, and advanced urinalysis technologies is expected to support broader implementation of automated urinalysis solutions in routine clinical practice.

Increasing Prevalence of Urinary Tract Infections

The rising prevalence of urinary tract infections (UTIs) is driving growth in the global urinalysis market by increasing the demand for rapid, accurate, and cost-effective diagnostic solutions for infection detection and management. Urinalysis plays a critical role in identifying UTIs by analyzing urine samples for indicators such as leukocytes, nitrites, bacteria, and other abnormalities, enabling timely treatment and reducing the risk of complications.

According to a study published by Springer, UTIs affect approximately 150 million people globally each year, with around 400 million cases occurring annually, and lifetime risk remains substantial, with about 6 in 10 women and 1 in 10 men experiencing at least one infection. The high disease burden is driving demand for routine urine testing across hospitals, diagnostic laboratories, and primary care settings, while also encouraging the adoption of advanced urinalysis technologies such as automated analyzers and point-of-care testing systems.

In June 2024, Community Health Center (CHC) Marwah launched a digital urine and blood analyzer to enhance diagnostic capabilities, supporting faster and more efficient detection of health conditions through advanced testing technologies. As healthcare providers focus on early diagnosis, antimicrobial stewardship, and improved infection management, the rising incidence of UTIs, along with advancements in diagnostic platforms, is expected to support faster diagnosis and improve infection management across healthcare facilities.

Restraint

Shortage of Skilled Laboratory Technicians

The shortage of skilled laboratory technicians is a significant restraint for the global urinalysis market as it can limit the efficient operation of diagnostic laboratories, delay test processing, and increase the risk of errors in manual urine analysis procedures. Urinalysis often requires trained professionals to perform sample preparation, operate diagnostic equipment, interpret complex results, and maintain quality control standards.

A lack of qualified personnel can reduce laboratory capacity, particularly in developing regions and healthcare facilities with limited resources, restricting access to timely diagnostic services. Additionally, the growing demand for urine-based testing due to the rising prevalence of kidney diseases, urinary tract infections, diabetes, and other chronic conditions is placing further pressure on existing laboratory staff.

Although automation, artificial intelligence, and point-of-care diagnostic technologies are helping reduce dependence on manual testing, the shortage of skilled technicians remains a challenge by raising operational costs, slowing adoption of advanced urinalysis systems, and affecting the overall efficiency of diagnostic workflows.

Urinalysis Market Trends & Opportunities

Growing Adoption of Rapid Point-of-Care (POC) and AI-Enabled Diagnostic Technologies

The growing adoption of rapid point-of-care (POC) and AI-enabled diagnostic technologies is emerging as a key trend in the global urinalysis market, driven by the need for faster, more accurate, and personalized diagnostic solutions. These advanced technologies are transforming traditional urine testing by enabling real-time analysis, improving clinical decision-making, reducing turnaround times, and supporting more targeted treatment approaches.

Rapid urinalysis platforms are particularly valuable for managing conditions such as urinary tract infections (UTIs), where timely identification of pathogens and appropriate antibiotic selection can improve patient outcomes and help address antimicrobial resistance. In April 2026, a study published in the Journal of Antimicrobial Chemotherapy evaluated a rapid urine test capable of identifying the most effective antibiotic for UTIs in under six hours, compared with the two to three days required for conventional culture methods.

The test demonstrated 97% agreement with standard laboratory testing across 352 urine samples and nearly 99% agreement in a second validation study involving 90 duplicate samples, highlighting its potential to enable same-day targeted antibiotic treatment and reduce unnecessary antibiotic use. The integration of rapid testing, artificial intelligence, and digital diagnostic capabilities is expected to further enhance the efficiency and accuracy of urinalysis, supporting the evolution of precision diagnostics and personalized patient care.

Increasing Adoption of High-Throughput, Automated, and Integrated Diagnostic Platforms

The growing adoption of high-throughput, automated, and integrated diagnostic platforms is emerging as a key trend in the global urinalysis market as clinical laboratories seek to improve operational efficiency, reduce manual workloads, and manage rising testing volumes with greater accuracy and consistency.

Automation and integrated diagnostic systems streamline sample processing, data analysis, and result reporting, enabling faster turnaround times while minimizing human error and supporting standardized laboratory workflows. These capabilities are becoming increasingly important as demand grows for urine-based testing for kidney diseases, urinary tract infections, diabetes, and other chronic conditions.

In December 2025, Roche launched the cobas® 6800/8800 Systems Version 2.0 following U.S. FDA 510(k) clearance, introducing software and workflow enhancements that improve laboratory efficiency, increase testing throughput, and expand assay flexibility. The upgraded systems can process up to 2,112 tests per day with an optional second analytic unit and support the simultaneous execution of laboratory-developed tests (LDTs) and in vitro diagnostic (IVD) assays through a unified user interface.

Such advancements reflect the broader industry shift toward scalable, automated, and integrated diagnostic platforms that enhance laboratory productivity while expanding deployment of integrated diagnostic platforms worldwide.

Expansion of Laboratory Automation and Smart Urinalysis Systems

The growing focus on laboratory automation is creating opportunities for the global urinalysis market by improving workflow efficiency, reducing manual intervention, and supporting higher testing volumes. Healthcare providers are increasingly adopting automated urine analyzers, urine chemistry analyzers, and point-of-care urine analyzers to deliver standardized, high-throughput testing with improved accuracy and faster turnaround times.

In addition, the growing availability of compact point-of-care urine analyzers is expanding access to diagnostic services in outpatient clinics, emergency departments, and primary healthcare settings. These technological advancements are supporting decentralized testing while enhancing laboratory productivity, making automated urinalysis solutions an important component of modern diagnostic workflows.

Segment Analysis

The global urinalysis market report is segmented based on product, test type, application, end user and region.

Continuous Demand for Disposable Testing Products

The consumables market segment accounted for the largest share of the global urinalysis market in 2025, representing 69% of the market, due to the continuous demand for disposable testing products such as urine reagent strips, urine dipsticks, urine collection containers, and urine test kits and other single-use components required for routine urinalysis procedures.

The high frequency of urine testing in hospitals, diagnostic laboratories, physician offices, and home-care settings drives recurring consumption of these products, making consumables a major revenue contributor. Additionally, the growing adoption of self-testing and point-of-care diagnostics is further supporting segment growth.

In October 2024, First Response launched the Multi Check Pregnancy Test Kit featuring EasyCup, an innovative urine-based pregnancy testing solution that combines a sample collection cup with an integrated test strip to simplify testing while providing reliable results. Such advancements in user-friendly urine testing products, along with strong demand for convenient, rapid, and accessible diagnostic solutions, are strengthening the dominance of the consumables segment in the global urinalysis market.

Increasing Adoption of Automated and Point-of-Care Urinalysis Systems

The instruments segment is growing in the global urinalysis market, expanding at a CAGR of 5.6%, driven by the wider adoption of automated, digital, and point-of-care urinalysis analyzers that improve testing speed, accuracy, and workflow efficiency. Growing demand for advanced diagnostic technologies, rising prevalence of kidney disorders and urinary tract infections, and the need for rapid clinical decision-making are encouraging healthcare facilities to invest in next-generation urinalysis instruments.

In January 2024, a published research paper titled “Development of a Quantitative Digital Urinalysis Tool for Detection of Nitrite, Protein, Creatinine, and pH” introduced a low-cost, smartphone-connected digital urinalysis tool that uses a portable transmission-based colorimeter to quantitatively measure key urinary biomarkers.

The system demonstrated the ability to detect nitrite, protein, creatinine, and pH within clinically relevant ranges, supporting point-of-care monitoring of urinary tract infections and kidney health through urinary protein-to-creatinine ratio measurements, while enabling secure cloud storage and web-based visualization of patient data. Such innovations highlight the shift toward digital urinalysis, connected diagnostic platforms, and decentralized testing, reinforcing the industry's transition toward intelligent diagnostic systems.

Shift Toward Modernizing Laboratory Workflows

The biochemical test market segment is the fastest-growing segment in the urinalysis market, expanding at a CAGR of 9.6%, due to the growing demand for rapid, accurate, and cost-effective detection of various health conditions, including kidney disorders, diabetes, urinary tract infections, and metabolic abnormalities.

Biochemical urine tests provide critical insights by analyzing parameters such as glucose, protein, ketones, bilirubin, pH, and creatinine, making them essential for routine screening, disease monitoring, and early diagnosis. The segment’s growth is further supported by advancements in digital and automated urinalysis technologies that enhance testing efficiency, reduce manual errors, and improve clinical workflows.

In August 2024, Alpha Laboratories Ltd. entered into a partnership with Clinical Design Technologies Ltd. to support the marketing and distribution of the world’s first digital closed urine testing system. This collaboration highlights the industry’s shift toward modernizing laboratory workflows through digital solutions that minimize sample handling, strengthen infection control, improve traceability, and streamline result reporting, thereby accelerating the adoption of advanced biochemical urinalysis systems across healthcare settings.

Integration of Sediment Analysis with Automated Urinalysis Systems

The sediment urinalysis segment is growing in the urinalysis market due to its critical role in detecting and monitoring kidney disorders, urinary tract infections (UTIs), and other urinary abnormalities through the identification of cells, casts, crystals, bacteria, and other microscopic components in urine. The rising prevalence of chronic kidney diseases, rising geriatric population, and growing emphasis on early diagnosis are driving demand for reliable urine sediment analysis across hospitals and diagnostic laboratories.

Additionally, advancements in automated urine sediment analyzers, digital imaging, and artificial intelligence (AI)-based particle recognition technologies are improving testing accuracy, reducing manual workload, and enabling faster results. The integration of sediment analysis with automated urinalysis systems is further enhancing laboratory efficiency, reducing manual intervention, and improving diagnostic accuracy across healthcare facilities.Top of Form

Geographical Penetration

North America Urinalysis Market: Driven by High Adoption of Innovative Diagnostic Technologies

North America is the largest region in the urinalysis market, accounting for 39% of the global market share in 2025, due to its advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and rising prevalence of chronic and urinary-related diseases. The growing burden of conditions such as bladder cancer, kidney disorders, and urinary tract infections is driving demand for early detection, routine screening, and disease monitoring solutions.

According to the American Cancer Society’s Cancer Facts & Figures 2025 report, approximately 84,870 new bladder cancer cases and 17,420 deaths were projected in the U.S. for 2025, emphasizing the need for effective diagnostic approaches. Additionally, technological advancements and regulatory clearances are supporting market expansion; in June 2026, OraSure Technologies, Inc. announced FDA clearance of its Colli-Pee Dx Urine Collection Kit from DNA Genotek for use with Roche’s molecular diagnostic tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on cobas® molecular diagnostic systems.

The solution enables convenient at-home urine sample collection while preserving sample integrity, improving accessibility to testing and supporting patient-centric diagnostic workflows. Rising healthcare investments, increased adoption of automated urinalysis systems, and growing demand for point-of-care and home-based testing solutions are further reinforcing North America’s dominance in the global urinalysis market.

Europe Urinalysis Market: Driven by Increasing Adoption of Advanced, Automated, and Connected Diagnostic Solutions

The urinalysis market in Europe is growing due to the widespread adoption of advanced, automated, and connected diagnostic solutions that enhance laboratory efficiency, workflow flexibility, and patient care. The rising demand for rapid and reliable urine testing for conditions such as urinary tract infections, kidney diseases, and metabolic disorders is encouraging healthcare facilities to upgrade their diagnostic capabilities.

Rising adoption of automated laboratory diagnostics, expanding preventive screening programs, and increasing investment in digital pathology are supporting demand for advanced urinalysis solutions across Europe. In April 2026, Sysmex Europe SE launched the UC-1100, a semi-automated urine chemistry analyser designed for routine urine testing in laboratories, clinics, and near-patient environments. The analyser expands Sysmex’s urinalysis portfolio by combining a compact design, intuitive operation, enhanced connectivity, and improved data traceability, enabling laboratories to integrate urine chemistry testing more efficiently into existing workflows.

With the ability to deliver urine chemistry results in less than one minute and support stand-alone or integrated laboratory configurations, the UC-1100 reflects the growing shift toward flexible, high-performance urinalysis systems across Europe. These technological advancements, along with the need for faster diagnostics and optimized laboratory operations, are accelerating laboratory modernization and wider adoption of advanced urinalysis technologies across Europe.

Asia-Pacific Urinalysis Market: Driven by Increasing Efforts to Improve Access to Healthcare in Primary Care Settings

Asia-Pacific is the fastest-growing region in the urinalysis market, expanding at a CAGR of 9.2%, driven by the rapid adoption of point-of-care diagnostics, rising prevalence of kidney diseases and pregnancy-related complications, and efforts to improve access to healthcare in primary care settings. The region is witnessing strong demand for affordable, portable, and technology-enabled urinalysis solutions that can support early disease detection and monitoring, particularly in areas with limited access to centralized laboratories.

In February 2026, the Technology Development Board (TDB) of India’s Department of Science and Technology, along with Odisha-based startup Prante Solutions, launched ProFlow-U, a point-of-care kidney health assessment platform designed for early detection and monitoring of kidney disease and pregnancy-related complications at the primary healthcare level.

The indigenous diagnostic platform integrates nano-sensor-based urine albumin and creatinine measurement kits with a portable urine analyzer featuring absorption and fluorescence technology, Bluetooth connectivity, Internet of Things (IoT) capabilities, and AI/ML-enabled mobile application support.

By providing rapid results without requiring samples to be sent to laboratories, ProFlow-U enables faster clinical decision-making and expands access to accurate kidney health assessments across primary healthcare centers, diagnostic networks, and antenatal care systems. Such innovations in low-cost, decentralized urinalysis technologies are expanding access to decentralized diagnostic testing across primary healthcare networks.

South America Urinalysis Market: Driven by Improvements in Laboratory Infrastructure

The urinalysis market in South America is growing due to the rising prevalence of chronic diseases, rising demand for early diagnosis, and expanding access to diagnostic healthcare services across the region. Urinalysis is widely adopted for the detection and monitoring of conditions such as urinary tract infections, kidney disorders, diabetes, and other metabolic diseases because it offers a cost-effective, non-invasive, and reliable diagnostic approach.

Continued healthcare investments, improvements in laboratory infrastructure, and the adoption of automated and point-of-care urinalysis systems are supporting market expansion by enabling faster and more accurate testing. Additionally, greater awareness of preventive healthcare, government initiatives to strengthen primary care services, and the need for affordable diagnostic solutions in emerging healthcare markets are supporting broader integration of urinalysis into routine diagnostic practice.

Middle East & Africa Urinalysis Market: Driven by Growing Prevalence of  Metabolic  Conditions

The urinalysis market in the Middle East & Africa is growing due to the rising burden of chronic diseases, greater healthcare investments, and the expansion of diagnostic infrastructure across the region. The high prevalence of conditions such as diabetes, kidney disorders, urinary tract infections, and other metabolic diseases is driving demand for routine urine testing for early detection and disease monitoring.

In addition, governments and healthcare organizations are focusing on improving access to diagnostic services, strengthening primary healthcare systems, and adopting advanced medical technologies to enhance patient outcomes. The broader adoption of automated urinalysis analyzers, point-of-care testing solutions, and cost-effective diagnostic tools is further supporting market growth by enabling faster and more accessible testing, particularly in areas with limited laboratory resources.

Furthermore, rising awareness of preventive healthcare and the need for efficient screening programs are contributing to the strengthening diagnostic capabilities across hospitals, clinics, and community healthcare facilities.

Key Developments

·         In February 2026, Bionote USA introduced the Vcheck U urinalysis analyzer, which provides both urine chemistry and sediment analysis for canine and feline patients in a single system. The analyzer can evaluate 15 chemistry and 16 sediment parameters within four minutes, offering detailed diagnostic insights for conditions such as metabolic disorders, kidney dysfunction, urinary tract infections, and kidney stones.

·         In February 2026, Labcorp launched an FDA-cleared rapid fentanyl visual urine test that provides acute care providers with results in 10 minutes to rapidly identify suspected fentanyl exposure.

·         In May 2026, Roche announced the launch of its comprehensive Liver Disease Panel, which combines biomarker-based diagnostics with advanced digital algorithms, including the CE-marked LiverPRO algorithm, to improve the identification and management of chronic liver disease. Designed to support timely fibrosis risk assessment, liver cancer surveillance, and evidence-based clinical decision-making, the platform reflects the broader trend toward integrated, non-invasive diagnostic solutions.